Vicore licenses idiopathic pulmonary fibrosis therapy to Nippon in Japan
Nippon will pay $10m upfront and up to $275m in milestone-based payments for the developmental and commercial rights to Vicore’s C21 in Japan.
Nippon will pay $10m upfront and up to $275m in milestone-based payments for the developmental and commercial rights to Vicore’s C21 in Japan.
What's Your Reaction?
